Metabolic and Non-Cognitive Manifestations of Alzheimer's Disease: The Hypothalamus as Both Culprit and Target of Pathology. Review uri icon

Overview

abstract

  • Alzheimer's disease (AD) is increasingly recognized as a complex neurodegenerative disease beginning decades prior to the cognitive decline. While cognitive deficits remain the cardinal manifestation of AD, metabolic and non-cognitive abnormalities, such as alterations in body weight and neuroendocrine functions, are also present, often preceding the cognitive decline. Furthermore, hypothalamic dysfunction can also be a driver of AD pathology. Here we offer a brief appraisal of hypothalamic dysfunction in AD and provide insight into an underappreciated dual role of the hypothalamus as both a culprit and target of AD pathology, as well as into new opportunities for therapeutic interventions and biomarker development.

publication date

  • September 10, 2015

Research

keywords

  • Alzheimer Disease
  • Biomarkers
  • Cognition
  • Neuroendocrine Cells

Identity

PubMed Central ID

  • PMC4654127

Scopus Document Identifier

  • 84948572757

Digital Object Identifier (DOI)

  • 10.1016/j.cmet.2015.08.016

PubMed ID

  • 26365177

Additional Document Info

volume

  • 22

issue

  • 5